Obesity-drug developer BioAge Labs Inc. gained about 20% after its initial public offering on Thursday, while natural-gas ...

Soaring demand for weight-loss drugs, expected to be a $150 billion market by early 2030s, has attracted more investors toward companies tapping into the lucrative market. The debut valued BioAge at ...

The U.S. IPO market has bounced back strongly in 2024 after a nearly two-year dry spell, driven by receding recession fears ...

The U.S. IPO market has experienced a significant resurgence in 2024 following nearly two years of stagnation. This recovery is largely due to reduced recession fears and a robust stock market rally.

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, visits the Nasdaq ...

Texas-based Barnett Shale driller BKV Inc. priced below the estimated range, while obesity-drug developer BioAge Labs Inc. priced midrange ahead of their first day of trading on Thursday. As the ...

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...

Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead ...